Drug Repurposing Series
Drug repurposing is a new trend in drug development. Compared with new drug development, drug repurposing has the following advantages: Drug safety has been widely verified at the clinical stage and in the pharmaceutical market, which reduces the risk of drug development failure caused by safety. The drugs have gone through systematic pre-clinical and clinical studies, with comprehensive research and complete data. Thus, they can greatly shorten the research and development cycle. Compared with development of new drugs for the same indication, drug repurposing can greatly save research costs.
MCE supplies several drug repurposing related libraries, including FDA Approved Drug Library, Clinical Compound Library and Drug Repurposing Compound Library, etc. All compounds in these libraries are supplied with detailed indications, clinical information and approved types to facilitate later research.
-
Withdrawn Drug Compound Library232 compoundsHY-L140
-
EMA-Approved Drug Library729 compoundsHY-L116
-
Pediatric Drug Library710 compoundsHY-L104
-
Drug Repurposing Compound Library5,147 compoundsHY-L035
-
Drug Repurposing Compound Library Plus6,147 compoundsHY-L035P
-
Clinical Compound Library2,564 compoundsHY-L026
-
Clinical Compound Library Plus3,292 compoundsHY-L026P
-
NMPA-Approved Drug Library1,536 compoundsHY-L053
-
FDA-Approved Drug Library Mini3,237 compoundsHY-L022M
-
FDA-Approved Drug Library3,237 compoundsHY-L022
-
FDA-Approved Drug Library Plus3,668 compoundsHY-L022P
-
FDA Approved & Pharmacopeial Drug Library3,750 compoundsHY-L066
-
Off-patent Drug Library2,920 compoundsHY-L141
-
FDA-Approved Anticancer Drug Library1,546 compoundsHY-L122
-
Classic FDA-Approved Drug Library168 compoundsHY-L261